Alethio Funds G6B Antibody Development for Essential Thrombocythemia

Company Alethio Therapeutics Event Type Series A financing ($90 million) Modality Monoclonal antibody Asset ATX-011 Target G6B Disease Area Essential thrombocythemia; myeloproliferative neoplasms Summary Alethio Therapeutics closed a $90 million Series A on November 5 to advance ATX-011, a G6B-targeting antibody, from IND-enabling studies into…